Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy – a multicenter report by the Polish Myeloma Study Group

References

• Laurent G, Morris C, Beksac M, et al. Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? A review from the chronic malignancies working party of the EBMT. Biol Blood Marrow Transplant. 2020;26(9):1559–1566.
   Web of Science ®Google Scholar
• Cook G, Williams C, Brown JM, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(8):874–885.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Baertsch MA, Schlenzka J, et al. Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide/dexamethasone for relapsed multiple myeloma: results of the randomized GMMG phase III multicenter trial relapse. Blood. 2018;132(Supplement 1):253.
   Web of Science ®Google Scholar
• Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013;19(5):760–766.
   PubMed Web of Science ®Google Scholar
• Grovdal M, Nahi H, Gahrton G, et al. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant. 2015;50(6):808–812.
   PubMed Web of Science ®Google Scholar
• Cook G, Liakopoulou E, Pearce R, et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2011;17(11):1638–1645.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Buadi FK, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019;54(3):353–367.
   PubMed Web of Science ®Google Scholar
• Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015;21(12):2039–2051.
   PubMed Web of Science ®Google Scholar
• Papanikolaou X, Rosenbaum ER, Tyler LN, et al. Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia. Leukemia. 2014;28(4):888–893.
   PubMed Web of Science ®Google Scholar
• Parrish C, Morris CT, Williams CD, et al. Stem cell harvesting after bortezomib-based reinduction for myeloma relapsing after autologous transplantation: results from the British Society of blood and marrow transplantation/United Kingdom myeloma forum myeloma X (intensive) trial. Biol Blood Marrow Transplant. 2016;22(6):1009–1016.
   PubMed Web of Science ®Google Scholar
• Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma. 2009;50(9):1442–1447.
   PubMed Web of Science ®Google Scholar
• Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009;43(5):417–422.
   PubMed Web of Science ®Google Scholar
• Morris C, Cook G, Streetly M, et al. Re-transplantation after bortezomib-based therapy. Br J Haematol. 2011;153(5):666–668.
   PubMed Web of Science ®Google Scholar
• Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012;118(14):3549–3555.
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Mikhael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18(5):773–779.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Gertz MA, Lacy MQ, et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant. 2013;48(4):568–573.
   PubMed Web of Science ®Google Scholar
• Lemieux E, Hulin C, Caillot D, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant. 2013;19(3):445–449.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica. 2006;91(1):141–142.
   PubMed Web of Science ®Google Scholar
• Elice F, Raimondi R, Tosetto A, et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol. 2006;81(6):426–431.
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006;106(5):1084–1089.
   PubMed Web of Science ®Google Scholar
• Fenk R, Liese V, Neubauer F, et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma. 2011;52(8):1455–1462.
   PubMed Web of Science ®Google Scholar
• Wirk B, Byrne M, Dai Y, et al. Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation. J Clin Med Res. 2013;5(3):174–184.
   PubMedGoogle Scholar
• Sahebi F, Iacobelli S, Sbianchi G, et al. Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents. Biol Blood Marrow Transplant. 2018;24(5):930–936.
   PubMed Web of Science ®Google Scholar
• Chung A, Liedtke M. Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Pract Res Clin Haematol. 2019;32(1):54–64.
   PubMed Web of Science ®Google Scholar
• Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2018;29(4):1074.
   PubMed Web of Science ®Google Scholar
• Auner HW, Szydlo R, Rone A, et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma. 2013;54(10):2200–2204.
   PubMed Web of Science ®Google Scholar